Heard On The Street: March 2011

Published on by on March 1, 2011

There was no shortage of activity in the ETF industry during the shortest month of the year, as a well-attended Florida conference brought together all the space’s major players. We learned quite a bit from the event, including some interesting speculation on the future of a struggling active ETF issuer, Scottrade’s attempts to play catch-up, and the latest on the SEC’s rapidly growing ETF-related to-do list.

February also brought some unexpected developments on the product front, with a number of new issues attracting significant interest from investors. The pipeline has continued to fill, and the recent debuts of some rather exotic and targeted products may prompt issuers to accelerate their product development timelines. The ETF iron remains red hot, and coming months could see a flurry of activity.

Pro Membership Required to Continue Reading ETFdb Pro

To continue reading this article, you must be an ETFdb Pro member. Please login or begin your 14-day free trial to continue reading. There are several benefits to becoming an ETFdb Pro member today:
  • Register on ETFdbAccess to 50+ All-ETF model portfolios. Whether you're a long-term, buy-and-hold investor or a more active trader looking to establish a tactical position, our collection of ETFdb Portfolios has something for everyone.
  • ETFdb Realtime Ratings show you exactly where each fund stacks up next to the competition. Get objective, in-depth, custom research on every ETF.
  • Pro members have Unlimited Excel Download capabilities across the entire database; users can easily download more than 200 data filled paged and also export results to Microsoft Excel from every tool.
  • Get ETF Picks of the Month. For active investors seeking ETF investment ideas, our team analyzes technical and fundamental price drivers of more than 1,400 ETFs to identify both short and longer-term opportunities with a focus on absolute returns. Recommendations are actionable investment ideas that are poised for outperformance over the next week to 90 days.

Begin Your Free 14-Day Trial Now